论文部分内容阅读
目的:评价乌司他丁对ICU重症肺炎患者白细胞计数、降钙素原水平及呼吸功能的影响。方法:选取医院ICU收治的重症肺炎患者70例作为研究对象,采用数字随机表法将患者分为对照组和治疗组,每组35例;对照组患者给予常规治疗,治疗组患者在对照组基础上给予乌司他丁治疗,评价两组患者治疗7 d后白细胞计数(WBC)、降钙素原(PCT)水平、C-反应蛋白(CRP)值的变化情况;记录两组患者呼吸频率(RR)、氧分压(Pa O2)及氧合指数(Pa O2/Fi O2)的变化情况,以及WBC、体温恢复时间及住院时间。结果:治疗组患者治疗7 d后WBC、PCT、CRP分别为(9.42±1.55)×109/L,(0.74±1.63)ng/m L和(29.84±11.93)mg/L低于对照组分别为(12.26±2.08)×109/L,(1.45±0.40)ng/m L和(41.68±13.87)mg/L(P<0.05);治疗组治疗后Pa O2、Pa O2/Fi O2分别为(12.41±1.03)k Pa,(37.11±2.96)k Pa高于对照组分别为(10.96±1.21)k Pa,(28.94±3.09)k Pa,RR为(18.63±2.41)次/min低于对照组为(24.58±2.69)次/min(P<0.05);治疗组患者WBC、体温恢复时间及住院时间短于对照组(P<0.05)。结论:乌司他丁能够降低ICU重症肺炎患者机体炎性水平,改善呼吸功能。
Objective: To evaluate the effect of ulinastatin on leukocyte count, procalcitonin and respiratory function in patients with severe pneumonia in ICU. Methods: Seventy patients with severe pneumonia admitted to the hospital ICU were selected as research objects. The patients were divided into control group and treatment group by digital random table method, 35 cases in each group. Patients in control group were given routine treatment. Patients in treatment group were basal in control group (WBC), procalcitonin (PCT) and C-reactive protein (CRP) in the two groups after treatment for 7 days. The respiratory rate RR, Pa O2 and Pa O2 / Fi O2, as well as WBC, body temperature recovery time and hospital stay. Results: The WBC, PCT and CRP were (9.42 ± 1.55) × 109 / L, (0.74 ± 1.63) ng / m L and (29.84 ± 11.93) mg / L respectively after treatment for 7 days in the treatment group were lower than those in the control group (12.26 ± 2.08) × 109 / L, (1.45 ± 0.40) ng / m L and (41.68 ± 13.87) mg / L respectively), the PaO2 and Pa O2 / Fi O2 were ± 1.03) kPa and (37.11 ± 2.96) kPa were significantly higher than those in the control group (10.96 ± 1.21 kPa and 28.94 ± 3.09 kPa, respectively, and RR was (18.63 ± 2.41) (24.58 ± 2.69) times / min (P <0.05). The WBC, body temperature recovery time and hospital stay in the treatment group were shorter than those in the control group (P <0.05). Conclusion: Ulinastatin can reduce the level of inflammation in ICU patients with severe pneumonia and improve respiratory function.